AbilityPharma has achieved a significant breakthrough by successfully developing a novel solid formulation presented in capsule form. This advancement replaces the previous liquid formulation, which caused unwanted taste effects and throat discomfort, particularly troublesome for pancreatic cancer patients with preexisting gastric and digestive issues. With this innovation, treatment adherence has improved, and patients' overall quality of life has been enhanced, as they can now avoid the unpleasant side effects associated with the previous formulation. So far, more than 100.000 capsules containing the active ingredient have been administered to approximately 100 patients with no safety issues reported.
AbilityPharma has reached another significant milestone by obtaining approval from all regulatory agencies in the countries participating in the study, Spain, France, USA and Israel. This validation confirms the study's safety and potential efficacy, as no major concerns have been reported during this process.
Despite significant delays in the initiation of Phase 2b, AbilityPharma took corrective measures by incorporating additional hospitals into the study to accelerate patient recruitment. As of today, the study is progressing exceptionally well, with over 80% of the total required patients already enrolled.
In a proactive effort to ensure smooth progress, AbilityPharma has diligently collected all the necessary regulatory documentation required by the EMA and the US FDA for the forthcoming application to conduct a Phase 3 trial. This comprehensive package of information is strategically prepared to facilitate license negotiation, positioning the project optimally for future agreements. AbilityPharma has initiated activities necessary to enable a future licensing agreement such as project dissemination and participation in partnering meetings.
Additionally, the interim analysis, specifically designed to accelerate negotiations by evaluating the study's efficacy and futility, has undergone significant improvements. With the inclusion of a larger patient cohort, the analysis now will yield more mature and valuable data, significantly enhancing the project's appeal during the negotiation phase.
Furthermore, AbilityPharma has initiated a biomarker program with the ultimate goal of identifying a gene mark capable of predicting treatment response. This development has the potential to significantly enhance the therapeutic effectiveness of their approach, opening up new possibilities for personalized treatment plans.
After the successful inclusion of approximately 80% of the intended patients, the study is expected to be completed by September 2024, signalling the availability of the results and the finals steps of licensing agreement negotiations.
